PUBLIC HEALTH REVIEWS

Epidemiology and etiology of childhood pneumonia

Epidémiologie et étiologie de la pneumonie chez l'enfant

Epidemiología y etiología de la neumonía en la niñez

Igor Rudan^I; Cynthia Boschi-Pinto^II; Zrinka Biloglav^III; Kim Mulholland^IV; Harry Campbell^{V, 1}

^ICroatian Centre for Global Health, University of Split Medical School, Soltanska 2, 21000 Split, Croatia
^IIChild and Adolescent Health and Development, World Health Organization, Geneva, Switzerland
^IIIDepartment of Epidemiology, Andrija Stampar School of Public Health, Zagreb, Croatia
^IVDepartment of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, England
^VUniversity of Edinburgh Medical School, Edinburgh, Scotland

ABSTRACT

Childhood pneumonia is the leading single cause of mortality in children aged less than 5 years. The incidence in this age group is estimated to be 0.29 episodes per child-year in developing and 0.05 episodes per child-year in developed countries. This translates into about 156 million new episodes each year worldwide, of which 151 million episodes are in the developing world. Most cases occur in India (43 million), China (21 million) and Pakistan (10 million), with additional high numbers in Bangladesh, Indonesia and Nigeria (6 million each). Of all community cases, 7–13% are severe enough to be life-threatening and require hospitalization. Substantial evidence revealed that the leading risk factors contributing to pneumonia incidence are lack of exclusive breastfeeding, undernutrition, indoor air pollution, low birth weight, crowding and lack of measles immunization. Pneumonia is responsible for about 19% of all deaths in children aged less than 5 years, of which more than 70% take place in sub-Saharan Africa and south-east Asia. Although based on limited available evidence, recent studies have identified Streptococcus pneumoniae, Haemophilus influenzae and respiratory syncytial virus as the main pathogens associated with childhood pneumonia.

RÉSUMÉ

La pneumonie est la principale cause simple de mortalité chez les enfants de moins de 5 ans. L'incidence dans cette tranche d'âge est estimée à 0,29 épisode/enfant/an dans les pays en développement et à 0,05 épisode/enfant/an dans les pays développés. Il en résulte environ 156 millions de nouveaux épisodes de pneumonie chaque année dans le monde, dont 151 millions dans les pays en développement. La plupart des cas se produisent en Inde (43 millions), en Chine (21 millions), au Pakistan (10 millions) et également en grands nombres au Bengladesh, en Indonésie et au Nigéria (6 million pour chacun de ces pays). Parmi l'ensemble des cas communautaires, 7 à 13 % sont assez graves pour menacer le pronostic vital et nécessiter une hospitalisation. De nombreux éléments ont fait apparaître comme facteurs de risque principaux pour l'incidence de la pneumonie l'absence d'allaitement au sein exclusif, la dénutrition, la pollution de l'air intérieur, le petit poids à la naissance, le surpeuplement et le manque de couverture par la vaccination antirougeoleuse. La pneumonie est responsable d'environ 19 % des décès d'enfants de moins de 5 ans, dont plus de 70 % se produisent en Afrique sub-saharienne et en Asie du Sud-est. Bien que reposant sur les données disponibles limitées, les études récentes ont identifié Streptococcus pneumonia, Haemophilus influenzae et le virus respiratoire syncytial comme les principaux agents pathogènes associés à la pneumonie de l'enfant.

RESUMEN

La neumonía es la principal causa única de mortalidad entre los menores de cinco años. Se estima que la incidencia en ese grupo de edad es de 0,29 episodios por niño y año en los países en desarrollo y de 0,05 episodios por niño y año en los países desarrollados. Ello se traduce en unos 156 millones de episodios nuevos cada año en todo el mundo, de los cuales 151 millones se registran en el mundo en desarrollo. La mayoría de los casos se dan en la India (43 millones), China (21 millones), el Pakistán (10 millones), y también presentan cifras altas Bangladesh, Indonesia y Nigeria (6 millones cada uno). De todos los casos comunitarios, un 7%-13% son lo bastante graves para poner en peligro la vida y requerir hospitalización. Numerosos datos demuestran que los principales factores de riesgo de la incidencia de neumonía son la falta de lactancia materna exclusiva, la desnutrición, la contaminación del aire en locales cerrados, el bajo peso al nacer, el hacinamiento y la falta de inmunización contra el sarampión. La neumonía provoca aproximadamente un 19% de todas las defunciones entre los niños menores de cinco años, y más del 70% de esas muertes se producen en el África subsahariana y en Asia sudoriental. Aunque la evidencia disponible es aún limitada, estudios recientes señalan a Streptococcus pneumoniae, Haemophilus influenzae y el virus sincitial respiratorio como los principales agentes patógenos asociados a la neumonía en la niñez.

Introduction

In the early 1970s Cockburn & Assaad¹ generated one of the earliest estimates of the worldwide burden of communicable diseases. In a subsequent review, Bulla & Hitze² described the substantial burden of acute respiratory infections and, in the following decade, with data from 39 countries, Leowski³ estimated that acute respiratory infections caused 4 million child deaths each year – 2.6 million in infants (0–1 years) and 1.4 million in children aged 1–4 years. In the 1990s, also making use of available international data, Garenne et al.⁴ further refined these estimates by modelling the association between all-cause mortality in children aged less than 5 years and the proportion of deaths attributable to acute respiratory infection. Results revealed that between one-fifth and one-third of deaths in preschool children were due to or associated with acute respiratory infection. The 1993 World Development Report⁵ produced figures showing that acute respiratory infection caused 30% of all childhood deaths.

The increasing focus on the reduction of child mortality arising from the Millennium Declaration and from the Millennium Development Goal (MDG) 4 of "reducing by two-thirds, between 1990 and 2015, the under-five mortality rate",⁶ has generated renewed interest in the development of more accurate assessments of the number of deaths in children aged less than 5 years by cause. Moreover, the monitoring of the coverage of interventions to control these deaths has become crucial if MDG 4 is to be achieved; thus a more accurate establishment of the causes of deaths in children aged less than 5 years becomes crucial. In 2001, WHO established the Child Health Epidemiology Reference Group (CHERG) – a group of independent technical experts, to systematically review and improve data collection, methods and assumptions underlying the estimates of the distribution of the main causes of death for the year 2000. In this paper, we summarize the findings of this group on the morbidity and mortality burden of childhood pneumonia. We also provide new regional and country pneumonia morbidity estimates for the year 2000, and review the current understanding of the distribution of the main etiological agents of pneumonia among children aged less than 5 years.

Search strategy and selection criteria

Most of the morbidity and mortality estimates in this paper are based on work published by CHERG's pneumonia working group.^7,8 As a first step, the group reviewed publications on childhood pneumonia and created a database including more than 2200 sources of information. Further details on the literature search strategies, inclusion criteria, methods and models used for estimating pneumonia burden were published elsewhere.^7–9 However, the results of the distribution of global pneumonia episodes by regions and countries with the prevalence of exposure to main risk factors have not yet been published. Thus, we present the details on methods and models used for estimating these disaggregated figures in Appendix A (available at: http://www.who.int/bulletin/volumes/86/5/07-048769/en/index.html). ^10–27

Incidence of clinical pneumonia

Rudan et al.⁸ calculated and published the first global estimate of the incidence of clinical pneumonia in children aged less than 5 years for the year 2000. This estimate was based on the analysis of data from selected 28 community-based longitudinal studies done in developing countries that were published between 1969 and 1999. These studies were the only sources meeting the predefined set of minimum-quality criteria for inclusion in the analysis.⁸ The estimated median incidence for developing countries was 0.28 episodes per child-year, with an interquartile range 0.21–0.71 episodes per child-year.⁸ The variation in incidence between the selected studies was very large, most probably due to the distinct study designs and real differences in the prevalence of risk factors in the various study settings. Given the substantial uncertainty over the point estimate, we used a triangular approach to check for plausibility of our assessment of pneumonia incidence. The ranges obtained by the main appraisal and two ancillary assessments overlapped between the values of 148 and 161 million new episodes per year. Giving most weight to the estimate obtained through the main approach, the analyses suggested that the incidence of clinical pneumonia in children aged less than 5 years in developing countries worldwide (WHO regions B, D and E; see Annex A) is close to 0.29 episodes per child-year. This equates to 151.8 million new cases every year, 13.1 million (interquartile range: 10.6–19.6 million) or 8.7% (7–13%) of which are severe enough to require hospitalization.⁸ In addition, a further 4 million cases occur in developed countries worldwide (all WHO regions A and Europe regions B and C). The regions and their populations are defined by WHO region and child and adult mortality stratum (Table 1 and the statistical annex of World Health Report 2000, available: at http://www.who.int/whr2001/2001/archives/2000/en/pdf/Statistical_Annex.pdf). ²²

It is of major public health interest to assess the distribution of these estimated 156 million episodes by regions and countries to assist planning for preventive interventions and case management at community and facility levels, including vaccine and antibiotic needs and delivery. Therefore, we calculated these figures with the model described in Appendix A. Table 2 shows the 15 countries with the highest predicted number of new pneumonia episodes and their respective incidence. These 15 countries account for 74% (115.3 million episodes) of the estimated 156 million global episodes. More than half of the world's annual new pneumonia cases are concentrated in just five countries where 44% of the world's children aged less than 5 years live: India (43 million), China (21 million) and Pakistan (10 million) and in Bangladesh, Indonesia and Nigeria (6 million each). Differences in incidence of childhood clinical pneumonia in the world at the country level are shown in Fig. 1.

Country estimates of the number of clinical pneumonia cases among children aged less than 5 years were assembled into six WHO regions (African Region, Region of the Americas, South-East Asia Region, European Region, Eastern Mediterranean Region and Western Pacific Region) as well as into developing and developed regions. These aggregated results together with estimates of new episodes per child-year and the number of severe episodes are shown in Table 1. Estimates of clinical pneumonia incidence are highest in South-East Asia (0.36 episodes per child-year), closely followed by Africa (0.33 episodes per child-year) and by the Eastern Mediterranean (0.28 episodes per child-year), and lowest in the Western Pacific (0.22 episodes per child-year), the Americas (0.10 episodes per child-year) and European Regions (0.06 episodes per child-year).

We explored the plausibility of the model estimates by computing incidence for more extreme values of risk-factor prevalence. When prevalence of exposure was set to 1% (an idealized scenario roughly similar to that in the most developed countries of the world), the incidence computed by the model was less than 0.05 episodes per child-year. This estimate is lower than those reported in two classic reports of clinical pneumonia incidence among children in the United States of America and in the United Kingdom in the 1970s and 1980s, respectively, and is close to our current estimate for the year 2000 for the European Region.^28,29 When the prevalence of exposure was set to 99% (an unrealistic scenario at the country level, even for the poorest countries of the world) the incidence computed by the model was about 0.77 episodes per child-year. This estimate is slightly above the upper limit of individually reported pneumonia incidence from the 28 community-based studies from the developing world (75% interquartile range estimate of 0.71 episodes per child-year). The model yields plausible estimates over a wide range of values of risk-factor prevalence, supporting its use for calculating the distribution of clinical pneumonia episodes.

Under-five mortality

Several attempts to understand worldwide child pneumonia mortality have been made over the past 30 years.^3–5,7,30 Despite the difficulties of producing estimates with available evidence, pneumonia has consistently been estimated as the leading single cause of childhood mortality. Some of the complexities for developing these estimates include large differences in case definition of pneumonia between studies, low specificity of verbal autopsies in community-based studies, the fact that similar symptoms from both pneumonia and malaria lead to death, difficulties in distinguishing pneumonia from sepsis in neonates and the synergy between several disorders leading to a single death.³¹

Two recent estimates of the total number of deaths due to clinical pneumonia have been made by CHERG. A single-cause model derived from 40 studies published between 1961 and 2000 and based on the relationship between the proportional mortality due to respiratory infections and the overall mortality in children aged less than 5 years, estimated the number of deaths attributable to childhood pneumonia to be 1.9 million in 2000.⁷ However, the data sources used to model the relationship between pneumonia proportional mortality and all-cause mortality were not representative of the whole world as most of the studies were from Latin America and only a few data points were from countries with very high all-cause mortality. Moreover, many of them had been done more than three decades ago, in the 1960s and 1970s. A multiple-cause model that analysed 38 more recent studies (average midstudy surveillance year of 1990) from sub-Saharan Africa and south Asia, in countries with mortality rates for children aged less than 5 years of at least 26 per 1000 live births, predicted a similar number of deaths attributable to pneumonia (i.e. approximately 1.8 million under-5 pneumonia deaths in these two regions in the year 2000).³²

Some evidence suggests, however, that both models underestimate the number of deaths attributable to clinical pneumonia in children aged less than 5 years. Many neonatal deaths have been attributed to severe infections³³ that have not been taken into account in these models (Fig. 2). The exact proportion of pneumonia among these infections has not been clearly established because of the difficulties in distinguishing causes among severe infections in newborns. However, at least another 300 000 deaths caused by pneumonia are likely to occur worldwide during the neonatal period (Lawn J, personal communication).

The interquartile range for available case-fatality ratios was 1.3–2.6%, leading to an estimated 1.96–3.92 million expected deaths from pneumonia per year based on the basis of observed incidence.⁸ Therefore, two lines of evidence both indicate that there are more than 2 million deaths due to pneumonia each year in children aged less than 5 years.

The relative importance of the different causes of death in children aged less than 5 years varies across regions of the world, although the major causes, such as pneumonia, remain the same (Fig. 2). As with the incidence of pneumonia, mortality is unequally distributed.⁶ The proportion of pneumonia-attributed deaths varies widely between WHO regions and significantly increases in relative importance in regions that have inefficient health systems (Fig. 2).

The African Region has, in general, the highest burden of global child mortality (Fig. 2). Although it comprises about 20% of the world's population of children aged less than 5 years,²² it has about 45% of global under-5 deaths and 50% of worldwide deaths from pneumonia in this age group.³⁴ By contrast, less than 2% of these deaths take place in the European Region and less than 3% in the Region of the Americas. More than 90% of all deaths due to pneumonia in children aged less than 5 years take place in 40 countries. Even more striking is the fact that, according to the official estimates from WHO for the year 2000, two-thirds of all these deaths are concentrated in just 10 countries³⁴: India (408 000 deaths), Nigeria (204 000), the Democratic Republic of the Congo (126 000), Ethiopia (112 000), Pakistan (91 000), Afghanistan (87 000), China (74 000), Bangladesh (50 000), Angola (47 000) and Niger (46 000; Table 3).

Although the absolute number of deaths provides important information regarding the global magnitude of the problem, it does not take into account the size of the population at risk and hence does not reflect the risk of death. For instance, while China has the seventh highest absolute number of pneumonia deaths in children aged less than 5 years, the mortality is about 8.6 per 10 000, whereas several countries have rates above 100 per 10 000.

Beyond inter-country inequities, further critical inequities are present within countries, where children from the poorest families, living in rural areas and whose mothers are less educated, are those more likely to die from pneumonia. Data on the distribution of causes of death within countries from the demographic and health surveys done in Bangladesh in 2004 show differentials in mortality due to acute respiratory infections by divisions, place of residence (rural/urban) and mother's education. Deaths due to acute respiratory infections were proportionately more common in the Sylhet division and least common in Rajshahi, with a 1.4-fold difference between the two. These infections were also a more common cause of death in rural (22.3%) than in urban (16.8%) areas. Furthermore, acute respiratory infection was associated with a large proportion of deaths among children of mothers with no education.³⁵

Causes of pneumonia in children

Childhood clinical pneumonia is caused by a combination of exposure to risk factors related to the host, the environment and infection. To identify the former two categories of causal factors for development of pneumonia at the community level, we used the methods described in steps 2–4 of Appendix A. We then established the following categories of risk factors for childhood pneumonia: definite (most evidence consistently pointing to the role of the risk factor); likely (most evidence consistently pointing to the role, but with some opposing findings; or scarce but consistent evidence of the role); and possible (with sporadic and inconsistent reports of the role in some contexts). These risk factors for development of pneumonia, related to the host or the environment, are listed in Box 1. In the remainder of this paper, we discuss etiological agents associated with childhood pneumonia.

Before vaccines were available, the cause of childhood pneumonia was a matter of great interest as specific therapy was available for pneumococcal pneumonia of certain serotypes, requiring not only an etiological diagnosis for effective therapy, but also pneumococcal serotyping. Studies from that era identified Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae as the main bacterial causes of pneumonia, with some severe cases caused by Staphylococcus aureus and Klebsiella pneumoniae.³⁶ In the modern era, our understanding of the causes of pneumonia in developing countries is based on two types of study. The first type consists of prospective hospital-based studies that have relied on blood cultures and, in some studies, of percutaneous lung aspiration.³⁷ Some other studies also examined nasopharyngeal specimens for virus identification.³⁸ This approach lacks sensitivity for the identification of bacterial cause. Attempts to augment culture-based methods with various indirect markers of bacterial cause have been largely unsuccessful as the tests employed have been unable to distinguish between carriage of pneumococcus and H. influenzae, which is usual for children in developing countries, and invasive disease.³⁹ The second type of study is the vaccine trial, in which the burden of pneumonia prevented by a specific vaccine is presumed to be a minimum estimate of the burden of pneumonia due to the organism against which the vaccine is directed.⁴⁰

In prospective, microbiology-based studies, the leading bacterial cause is pneumococcus, being identified in 30–50% of pneumonia cases.^36,37,41–45 The second most common organism isolated in most studies is H. influenzae type b (Hib; 10–30% of cases), followed by S. aureus and K. pneumoniae. In addition, lung aspirate studies have identified a significant fraction of acute pneumonia cases to be due to Mycobacterium tuberculosis, which is notoriously difficult to identify in children.⁴⁵ Controversy surrounds the role of three important organisms, non-typable H. influenzae (NTHI), S. aureus and non-typhoid Salmonella spp. NTHI was found to be an important pathogen in a lung aspirate study from Papua New Guinea,⁴³ whereas in a series of lung aspirate studies from the Gambia, and in most blood culture-based studies, Hib was the main type of H. influenzae identified.³⁷ Studies from Pakistan found NTHI to be a common blood culture isolate,^46,47 but this has not been replicated elsewhere. The first major study of the modern era that used lung aspiration on over 500 children in Chile, including normal controls, found S. aureus to be the main pathogen.⁴⁸ This finding has not been replicated in more recent studies, although a recently completed WHO study of very severe (hypoxaemic) pneumonia in seven countries found S. aureus in 47 of the 112 cases (42% of cases) in which a bacterium was identified, making it the second largest cause.⁴⁹ The role of non-typhoid Salmonella spp. is also unclear. Studies from Africa have shown bacteraemia caused by non-typhoid Salmonella spp. to be common^50,51 and often associated with malaria. Although the work of Graham et al.⁵² in Malawi has implicated non-typhoid Salmonella spp. in radiological pneumonia cases, the role of these organisms in pneumonia is still unclear, as blood-culture studies have focused on children with fever and fast breathing and, therefore, may have identified children with bacteraemia only.⁵³

The two causes of bacterial pneumonia that are vaccine-preventable are Hib and pneumococcus.^54–60 In both cases, the vaccines will prevent most pneumonia due to each pathogen, and microbiological methods will detect only a few cases. Thus, the vaccine probe concept has emerged to describe studies that are designed to determine the burden of pneumonia that can be prevented by the vaccine, and is therefore attributable to the organism. These studies have used the WHO definition of radiological pneumonia as the main outcome. For Hib, two randomized controlled trials,^54,55 one open trial,⁵⁶ a case–control study with random allocation of vaccine⁵⁷ and several other case–control studies have led to the conclusion that, in developing countries with a high burden of pneumonia, 15–30% of radiological pneumonia cases, and probably the same proportion of pneumonia deaths, are due to Hib. For pneumococcus, three randomized controlled trials in developing countries have shown that the nine-valent pneumococcal conjugate vaccine can prevent 20–35% of radiological pneumonia cases and probably a similar proportion of pneumonia deaths.^58–60 The newer pneumococcal vaccines covering 10–13 serotypes will likely extend this protection considerably. In addition, one of the vaccines contains elements that may prevent non-typable H. influenzae pneumonia as well. Thus, future pneumococcal vaccines may prevent 30–50% of radiological and fatal pneumonia. WHO has recently established modelled estimates of the number of pneumonia cases and deaths that are attributable to these organisms on a country-by-country basis. These estimates will be available soon (Kate O'Brien, Thomas Cherian and Maria D Knoll, personal communications).

Pneumonia etiology studies that incorporate viral studies show that respiratory syncytial virus is the leading viral cause, being identified in 15–40% of pneumonia or bronchiolitis cases admitted to hospital in children in developing countries, followed by influenza A and B, parainfluenza, human metapneumovirus and adenovirus.^38,61,62 In the prospective microbiology-based studies, viral causes of pneumonia are identified by rapid diagnostic tests (such as indirect immunofluorescence, enzyme-linked immunosorbent assay, polymerase chain reaction, viral culture on upper respiratory secretions – such as in nasopharyngeal aspirates – or by viral serology in paired samples).^38,61 It will be some time before any of these causes are preventable by routine immunization.

Weber et al.³⁸ made the most informative overview of respiratory syncytial virus. Because this virus is fragile, it is difficult to detect and its importance is probably underestimated. It was found in substantial frequency in all climatic and geographical areas, with sharp peaks of activity over a period of 2–4 months, but its seasonality varies considerably between regions. The peaks typically occur in the cold season in temperate climates and in the rainy season in tropical climates. Disease burden estimates from vaccine-probe studies are not yet available as for Hib and pneumococcus, but such data may become available from monoclonal antibody trials, which show high efficacy against severe disease caused by respiratory syncytial virus. Primary respiratory infection by this virus increases the risk of secondary bacterial pneumonia and viral or bacterial coinfection is a common finding in young children with pneumonia in developing countries (approximately 20–30% of episodes).^41,46 Furthermore, episodes of wheezing due to reactive airways are more common after such episodes. Some two-thirds of the episodes are seen in the first year of life, with 1.5–1.8 times greater frequency in boys than in girls. This implies that any vaccination efforts would need to be made early in life. The risk of pneumonia or bronchiolitis caused by respiratory syncytial virus is highest among children aged less than 2 years with the most severe disease occurring in infants aged 3 weeks to 3 months.^63,64 A recent postmortem study of lung tissue samples from 98 Mexican children aged less than 2 years who died of pneumonia, which used nested polymerase chain reactions, showed that 30% were positive for respiratory syncytial virus: 62% of those with histopathological diagnosis of viral pneumonia and 25% with diagnosis of bacterial pneumonia.⁶⁵ This study reaffirmed the role of respiratory syncytial virus as a very significant and potentially deadly pathogen that causes childhood pneumonia, both alone and through mixed infections with bacterial causes.

In recent years, the HIV epidemic has also contributed substantially to increases in incidence and mortality from childhood pneumonia. In children with HIV, bacterial infection remains a major cause of pneumonia mortality, but additional pathogens (e.g. Pneumocystis jiroveci) are also found in HIV-infected children,^66,67 while M. tuberculosis remains an important cause of pneumonia in children with HIV and uninfected children.⁶³ Available vaccines have lower efficacy in children infected with HIV, but still protect a significant proportion against disease.⁶⁷ Antiretroviral programmes can reduce the incidence and severity of HIV-associated pneumonia in children through the prevention of HIV infection, use of co-trimoxazole prophylaxis and treatment with antiretrovirals.⁶⁷

Other organisms, such as Mycoplasma pneumoniae, Chlamydia spp., Pseudomonas spp., Escherichia coli, and measles, varicella, influenza, histoplasmosis and toxoplasmosis, also cause pneumonia. Most of them are not preventable, but immunization against measles, influenza and possibly use of bacille Calmette–Guérin (BCG) have probably contributed substantially to decreasing the pneumonia burden. There are few data on the causes of neonatal pneumonia in developing countries, but studies of neonatal sepsis suggest that these include Gram-negative enteric organisms, particularly Klebsiella spp, and Gram-positive organisms, mainly pneumococcus, group b Streptococcus and S. aureus.⁶⁸

Conclusions

About 156 million new episodes of childhood clinical pneumonia occurred globally in 2000, more than 95% of them in developing countries. Of all the pneumonia cases occurring in those countries, 8.7% are severe enough to be life-threatening and require hospital admission. About 2 million pneumonia deaths occur each year in children aged less than 5 years, mainly in the African and South-East Asia Regions. The main bacterial causes of clinical pneumonia in developing countries are S. pneumoniae and Hib, and the main viral cause is respiratory syncytial virus, but estimates of their relative importance vary in different settings. The only vaccines for the prevention of bacterial pneumonia (excluding pertussis) are Hib and pneumococcal vaccines. Future studies, with new molecular techniques to better detect infections due to the wide range of pathogens, will broaden our understanding of the cause of pneumonia and may highlight which pathogens should be the targets for new vaccines. Despite the lack of data, mainly for the developing regions of the world, morbidity and mortality estimates and the main risk factors presented in this review could contribute to an understanding of the burden of acute lower respiratory infections in children aged less than 5 years in developing countries and to informed care and vaccine policy.

Acknowledgements

We thank Walter Mendoza, Tessa Wardlaw and Emily White for supplying some of the relevant MICS and DHS data, Lana Tomaskovic for assisting in the development of the literature review database, Ozren Polasek for producing the artwork, Shamim Qazi for his diligent review of the paper and valuable input and comments.

Most information contained in this paper builds on previous work conducted in collaboration with or by working groups from the Child Health Epidemiology Reference Group (CHERG), established and coordinated by the Department of Child and Adolescent Health and Development of WHO, with financial support from the Bill & Melinda Gates Foundation. We thank CHERG leaders and members for initiating all this work.

Funding: Igor Rudan and Zrinka Biloglav were supported by a Croatian Ministry of Science, Education and Sport grant (No. 108–1080315–0302) and a Croatian National Science Foundation scholarship.

Competing interests: None declared.

References

1. Cockburn WC, Assaad F. Some observations on the communicable diseases as public health problems. Bull World Health Organ 1973;49:1-12. PMID:4545151        

2. Bulla A, Hitze KL. Acute respiratory infections: a review. Bull World Health Organ 1978;56:481-98. PMID:308414        

3. Leowski J. Mortality from acute respiratory infections in children under 5 years of age: global estimates. World Health Stat Q 1986;39:138-44. PMID:3751104        

4. Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q 1992;45:180-91. PMID:1462653        

5. Investing in health: the world development report. Washington, DC: World Bank; 1993.         

6. United Nations Millennium Development Goals. Available from: http://www.un.org/millenniumgoals/ [accessed on 1 April 2008]          .

7. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2:25-32. PMID:11892493 doi:10.1016/S1473-3099(01)00170-0        

8. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ 2004;82:895-903. PMID:15654403        

9. Rudan I, Lawn J, Cousens S, Rowe AK, Boschi-Pinto C, Tomaskovic L, et al. Gaps in policy-relevant information on burden of disease in children: a systematic review. Lancet 2005;365:2031-40. PMID:15950717 doi:10.1016/S0140-6736(05)66697-4        

10. Ballard TJ, Neumann CG. The effects of malnutrition, parental literacy and household crowding on acute lower respiratory infections in young Kenyan children. J Trop Pediatr 1995;41:8-13. PMID:7723139        

11. Zaman K, Baqui AH, Yunus M, Sack RB, Bateman OM, Chowdhury HR, et al. Association between nutritional status, cell-mediated immune status and acute lower respiratory infections in Bangladeshi children. Eur J Clin Nutr 1996;50:309-14. PMID:8735312        

12. Selwyn BJ. The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Rev Infect Dis 1990;12 Suppl 8;S870-88. PMID:2270410        

13. Tupasi TE, de Leon LE, Lupisan S, Torres CU, Leonor ZA, Sunico ES, et al. Patterns of acute respiratory tract infection in children: a longitudinal study in a depressed community in Metro Manila. Rev Infect Dis 1990;12 Suppl 8; S940-8. PMID:2270416        

14. Hortal M, Benitez A, Contera M, Etorena P, Montano A, Meny M. A community-based study of acute respiratory tract infections in children in Uruguay. Rev Infect Dis 1990;12 Suppl 8;S966-72. PMID:2270419        

15. Singh MP, Nayar S. Magnitude of acute respiratory infections in under five children. J Commun Dis 1996;28:273-8. PMID:9057452        

16. Fonseca W, Kirkwood BR, Victora CG, Fuchs SR, Flores JA, Misago C. Risk factors for childhood pneumonia among the urban poor in Fortaleza, Brazil: a case - control study. Bull World Health Organ 1996;74:199-208. PMID:8706236        

17. Victora CG, Barros FC, Kirkwood BR, Vaughan JP. Pneumonia, diarrhea, and growth in the first 4 y of life: a longitudinal study of 5914 urban Brazilian children. Am J Clin Nutr 1990;52:391-6. PMID:2375306        

18. Murtagh P, Cerqueiro C, Halac A, Avila M, Salomon H, Weissenbacher M. Acute lower respiratory infection in Argentinian children: a 40 month clinical and epidemiological study. Pediatr Pulmonol 1993;16:1-8. PMID:8414734 doi:10.1002/ppul.1950160102        

19. Oyejide CO, Osinusi K. Acute respiratory tract infection in children in Idikan Community, Ibadan, Nigeria: severity, risk factors and severity of occurrence. Rev Infect Dis 1990;12 Suppl 8;S1042-6. PMID:2270403        

20. Cunha AL. Relationship between acute respiratory infection and malnutrition in children under 5 years of age. Acta Paediatr 2000;89:608-9. PMID:10852201 doi:10.1080/080352500750027943        

21. Dharmage SC, Rajapaksa LC, Fernando DN. Risk factors of acute lower respiratory tract infections in children under five years of age. Southeast Asian J Trop Med Public Health 1996;27:107-10. PMID:9031411        

22. World population prospects: population database. United Nations Population Division; 2006. Available from: http://esa.un.org/unpp [accessed on 1 April 2008]          .

23. Demographic and Health Survey. Calverton, MD; ORC Macro. Available from: http://www.measuredhs.com [accessed on 1 April 2008]          .

24. Multiple Indicators Cluster Survey (MICS). New York, NY: UNICEF. Available from: http://www.unicef.org/statistics/index_24302.html [accessed on 1 April 2008]          .

25. WHO database. Available from: http://www.who.int/whosis/database/core/core_select.cfm [accessed on 1 April 2008]          .

26. Indoor air pollution: National burden of disease estimates. Geneva: WHO; 2007 (WHO/SDE/PHE/07.01.rev).         

27. Rothman KJ, Greenland S. Modern epidemiology. 2nd edn. New York: Lippincott, Williams & Wilkins Publishers; 1998.         

28. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973;288:498-505. PMID:4346164        

29. Anderson HR. Respiratory disease in childhood. Br Med Bull 1986;42:167-71. PMID:3527328        

30. Bryce J, Boschi-Pinto C, Shibuya K, Black RE; WHO Child Health and Epidemiology Research Group. WHO estimates of the causes of death in children. Lancet 2005;365:1147-52. PMID:15794969 doi:10.1016/S0140-6736(05)71877-8        

31. Lanata CF, Rudan I, Boschi-Pinto C, Tomaskovic L, Cherian T, Weber M, et al. Methodological and quality issues in epidemiological studies of acute lower respiratory infections in children in developing countries. Int J Epidemiol 2004;33:1362-72. PMID:15166188 doi:10.1093/ije/dyh229        

32. Morris SS, Tomaskovic L, Black RE. Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems. Int J Epidemiol 2003;32:1041-51. PMID:14681271 doi:10.1093/ije/dyg241        

33. Lawn JE, Wilczynska-Ketende K, Cousens SN. Estimating the causes of 4 million neonatal deaths in the year 2000. Int J Epidemiol 2006;35:706-18. PMID:16556647 doi:10.1093/ije/dyl043        

34. World health statistics. Geneva: WHO; 2007. Available from: http://www.who.int/whosis/whostat2007.pdf [accessed on 1 April 2008]          .

35. Bangladesh Demographic and Health Survey 2004. National Institute of Population Research and Training. Dhaka/Calverton, MD: Mitra & Associates/ORC Macro; 2005.         

36. Shann F. Etiology of severe pneumonia in children in developing countries. Pediatr Infect Dis J 1986;5:247-52.         

37. Adegbola RA, Falade AG, Sam BE, Aidoo M, Baldeh I, Hazlett D, et al. The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr Infect Dis J 1994;13:975-82. PMID:7845751        

38. Weber MW, Mulholland KE, Greenwood BM. Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health 1998;3:268-80. PMID:9623927 doi:10.1046/j.1365-3156.1998.00213.x        

39. Goldblatt D, Miller E, McCloskey N, Cartwright K. Immunological response to conjugate vaccines in infants: follow up study. BMJ 1998;316:1570-1. PMID:9596595        

40. Mulholland EK. Use of vaccine trials to estimate burden of disease. J Health Popul Nutr 2004;22:257-67. PMID:15609778        

41. Forgie IM, O'Neill KP, Lloyd-Evans N, Leinonen M, Campbell H, Whittle HC, et al. Etiology of acute lower respiratory tract infections in Gambian children: I. Acute lower respiratory tract infections in infants presenting at the hospital. Pediatr Infect Dis J 1991;10:33-41. PMID:1848364        

42. Forgie IM, O'Neill KP, Lloyd-Evans N, Leinonen M, Campbell H, Whittle HC, et al. Etiology of acute lower respiratory tract infections in Gambian children: II. Acute lower respiratory tract infection in children ages one to nine years presenting at the hospital. Pediatr Infect Dis J 1991;10:42-7. PMID:2003054        

43. Shann F, Gratten M, Germer S, Linnemann V, Hazlett D, Payne R. Etiology of pneumonia in children in Goroka Hospital, Papua New Guinea. Lancet 1984;2:537-41. PMID:6147602 doi:10.1016/S0140-6736(84)90764-5        

44. Kamiya Y, Mtitimila E, Graham SM, Broadhead RL, Brabin B, Hart CA. Pneumocystis carinii pneumonia in Malawian children. Ann Trop Paediatr 1997;17:121-6. PMID:9230974        

45. Falade AG, Mulholland EK, Adegbola RA, Greenwood BM. Bacterial isolates from blood and lung aspirate cultures in Gambian children with lobar pneumonia. Ann Trop Paediatr 1997;17:315-9. PMID:9578790        

46. Ghafoor A, Nomani NK, Ishaq Z, Zaidi SZ, Anwar F, Burney MI, et al. Diagnoses of acute lower respiratory tract infections in children in Rawalpindi and Islamabad, Pakistan. Rev Infect Dis 1990;12 Suppl 8;S907-14. PMID:2270413        

47. Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. Lancet 1998;352:270-4. PMID:9690406 doi:10.1016/S0140-6736(97)10294-X        

48. Mimica I, Donoso E, Howard JE, Ledermann GW. Lung puncture in the etiological diagnosis of pneumonia. A study of 543 infants and children. Am J Dis Child 1971;122:278-82. PMID:4398908        

49. Asghar R, Banajeh S, Egas J, Hibberd P, Iqbal I, Katep-Bwalya M, et al. Multicentre randomized controlled trial of chloramphenicol vs. ampicillin and gentamicin for the treatment of very severe pneumonia among children aged 2 to 59 months in low resource settings: a multicenter randomized trial (spear study). BMJ 2008;336:80-4. PMID:18182412 doi:10.1136/bmj.39421.435949.BE        

50. Graham SM, Molyneux EM, Walsh AL, Cheesbrough JS, Molyneux ME, Hart CA. Nontyphoidal Salmonella infections of children in tropical Africa. Pediatr Infect Dis J 2000;19:1189-96. PMID:11144383 doi:10.1097/00006454-200012000-00016        

51. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005;352:39-47. PMID:15635111 doi:10.1056/NEJMoa040275        

52. Graham SM, Walsh AL, Molyneux EM, Phiri AJ, Molyneux ME. Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. Trans R Soc Trop Med Hyg 2000;94:310-4. PMID:10975008 doi:10.1016/S0035-9203(00)90337-7        

53. O'Dempsey TJ, McArdle TF, Lloyd-Evans N, Baldeh I, Laurence BE, Secka O, et al. Importance of enteric bacteria as a cause of pneumonia, meningitis and septicemia among children in a rural community in The Gambia, West Africa. Pediatr Infect Dis J 1994;13:122-8. PMID:8190537        

54. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type B tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-7. PMID:9130939 doi:10.1016/S0140-6736(96)09267-7        

55. Gessner BD, Sutanto A, Linehan M, Djelantik IG, Fletcher T, Gerudug IK, et al. Incidences of vaccine-preventable Haemophilus influenzae type B pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005;365:43-52. PMID:15643700 doi:10.1016/S0140-6736(04)17664-2        

56. Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996;15:216-22. PMID:8852909 doi:10.1097/00006454-199603000-00008        

57. Baqui AH, El Arifeen S, Saha SK, Persson L, Zaman K, Gessner BD, et al. Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J 2007;26:565-71. PMID:17596795 doi:10.1097/INF.0b013e31806166a0        

58. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365:1139-46. PMID:15794968 doi:10.1016/S0140-6736(05)71876-6        

59. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-8. PMID:14523142 doi:10.1056/NEJMoa035060        

60. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005;40:1511-8. PMID:15844075 doi:10.1086/429828        

61. Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847-52. PMID:10485741        

62. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 2003; 22:S21-32. PMID:12671449 doi:10.1097/00006454-200302001-00004        

63. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 2003;22:S40-5. PMID:12671451 doi:10.1097/00006454-200302001-00006        

64. Weisman LE. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Pediatr Infect Dis J 2003;22:S33-9. PMID:12671450 doi:10.1097/00006454-200302001-00005        

65. Bustamante-Calvillo ME, Velázquez FR, Cabrera-Munõz L, Torres J, Gómez-Delgado A, Moreno JA et al. Molecular detection of respiratory syncytial virus in postmortem lung tissue samples from Mexican children deceased with pneumonia. Pediatr Infect Dis J 2001;20:495-501. PMID:11368106        

66. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007;20:11-5. PMID:17197876 doi:10.1097/QCO.0b013e328012c5f1        

67. Zar HJ, Madhi SA. Childhood pneumonia – progress and challenges. S Afr Med J 2006;96:890-900. PMID:17077915        

68. The WHO Young Infants Study Group. Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. Pediatr Infect Dis J 1999;18 Suppl;S17-22. PMID:10530569 doi:10.1097/00006454-199910001-00004        

(Submitted: 18 October 2007 – Revised version received: 14 January 2008 – Accepted: 5 March 2008)

1 Correspondence to Igor Rudan (e-mail: irudan@hotmail.com).
doi:10.2471/BLT.07.048769

Click to enlarge